Deutsche Märkte geschlossen

Gilead Sciences, Inc. (GIS.F)

Frankfurt - Frankfurt Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
62,04+0,13 (+0,21%)
Börsenschluss: 11:49AM CEST

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Sektor(en)Healthcare
BrancheDrug Manufacturers - General
Vollzeitmitarbeiter18.000

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Daniel P. O'DayChairman & CEO6,55MN/A1964
Mr. Andrew D. DickinsonChief Financial Officer2,5MN/A1970
Ms. Deborah H. TelmanExecutive VP of Corporate Affairs, General Counsel & Corporate Secretary2,4MN/A1965
Ms. Johanna MercierChief Commercial Officer2,9MN/A1970
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer2,62MN/A1964
Ms. Sandra PattersonSenior VP, Corporate Controller & Principal Accounting OfficerN/AN/A1967
Ms. Jacquie Ross C.F.A.Vice President of Investor RelationsN/AN/AN/A
Ms. Jyoti K. MehraExecutive Vice President of Human ResourcesN/AN/A1976
Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & PortfolioN/AN/A1962
Dr. Rudolf ErtlSenior Vice President of Commercial Operations of Australia, Canada, EuropeN/AN/A1946
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Corporate Governance

Gilead Sciences, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 1. Die grundlegenden Scores sind Audit: 3, Vorstand: 5, Shareholderrechte: 1, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.